Claudin6

We offer a range of high-quality Claudin6 CAR-related products and services that are instrumental in the design, development, and evaluation of CAR therapies targeting Claudin6. Please refer to the following items to choose the appropriate products that you desire.

Background

Claudin6 is a protein that belongs to the claudin family, which are integral membrane proteins that play a critical role in the formation of tight junctions between cells. Tight junctions are specialized structures that seal the spaces between cells, regulating the passage of ions and molecules across cell layers. Claudin6 is specifically involved in the regulation of paracellular permeability in epithelial and endothelial cells, helping to maintain the barrier function of tissues and organs. Aberrant expression of claudin-6 has been associated with various diseases, including liver, ovarian, endometrial, and oesophageal cancer, and atypical teratoid/rhabdoid tumors. Featured with its crucial biological functions, Claudin6 has emerged as an attractive therapeutic target for many cancers.

Fig.1 qPCR expression test of Claudin6 transcripts in human normal tissues and ovarian cancer.¹

Associated Diseases

• Liver Cancer
• Ovarian Cancer
• Endometrial Cancer
• Others

Anti-Claudin6 CAR-T Assay Services

To accelerate CART development, we offer a range of custom service solutions to facilitate the development of personalized CAR-T cell therapies. Our services include:

Anti-Claudin6 CAR-T In Vitro Assays

• Claudin6 CAR Design & Construction

Creative Biolabs specializes in designing CAR constructs tailored to target specific antigens expressed by cancer cells, including classical CAR design, armored CAR constructions, etc. Our team of experts custom CAR structure with optimized binding affinities and signaling domains to enhance treatment efficacy.

Fig.2 Schematic diagram of Claudin6 CAR construction.¹

• Anti-Claudin6 CAR Expression Assay

For the CART expression test, Creative Biolabs has launched many sensitive CAR detection reagents (e.g., antigen-specific detection reagents, and universal reagents like anti-mouse/human Fab antibodies). In addition, we offer CAR expression detection services utilizing comprehensive techniques to accurately assess CAR expression levels.

• Anti-Claudin6 CAR-T Proliferation Detection

Analyzing the expansion and proliferation of CAR T cells in vitro will provide valuable insights into their function and potential for therapeutic applications. Creative Biolabs is dedicated to providing CART proliferation tests with several approaches (e.g., CFSE-based proliferation test, CCK-8 assay, MTT assay) to meet specific client needs, accommodating different types of CAR constructs, antigens, and cell types to ensure a precise and comprehensive evaluation.

Fig.3 Proliferation test of Claudin6 CAR-transduced T cells detected by flow cytometry after 5 days.¹

• Anti-Claudin6 CAR-T Cytokine Release Test

Cytokine release test is a vital tool for evaluating the performance and efficacy of CAR-T cells against target cells. Our services include utilizing several techniques like Enzyme-Linked Immunosorbent Assay (ELISA), multiplex bead arrays, and intracellular cytokine analysis by flow cytometry to measure and analyze the cytokine release profile.

Fig.4 Cytokine detection of Claudin6-CART cells co-culture with claudin-expressing DCs analyzed by a multiplex assay.¹

• Anti-Claudin6 CAR-T In Vitro Cytotoxicity Assay

CART cell in vitro cytotoxicity assay is a widely used technique to assess the killing capability of CAR-T cells toward target cells. We offer several methods to analyze the cytotoxicity of CAR-T cells, such as the flow cytometry-based assay, chromium release assay, and luminescence-based assay.

Fig.5 In vitro dynamic killing assessment of Claudin6 CAR-T cells against Claudin6 positive tumor spheroids at 10:1 E:T ratio.¹

Anti-Claudin6 CAR-T In Vivo Assays

More importantly, Creative Biolabs offers comprehensive CART in vivo study services, which involve the use of appropriate animal models to assess the efficacy and functionality of CAR-T cells in vivo, offering important data for evaluating the therapeutic potential of CAR-T cell therapies in a preclinical setting.

Fig.6 In vivo efficacy of anti-Claudin6 CAR-T in Claudin6 expressing OV90 cell CDX model. Claudin6 expressing OV90 cells and CART cell characteristics (left and middle) and tumor growth kinetics of CDX model (right) were analyzed.¹

Reference

1. Reinhard, Katharina, et al. "An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors." Science 367.6476 (2020): 446-453.